• EN/ES

    Orthopedics

    WebHealthNetwork : 2,378,479


  • Benefits & Savings

  • : Abdominal Neoplasms

Abdominal Neoplasms - 350 Studies Found

Completed : Combination Chemotherapy in Treating Patients With Untreated Ovarian, Peritoneal, or Fallopian Tube Cancer
:
  • Fallopian Tube Cancer
  • Ovarian Cancer
  • Primary Peritoneal Ca
    : 1999-11-01
    :
    • Drug: carboplatin
    • Drug: paclitaxel

Terminated : Combination Chemotherapy Consisting of Gemcitabine And Topotecan in Treating Patients With Refractory or Recurrent Ovarian or Fallopian Tube Cancer
:
  • Fallopian Tube Cancer
  • Ovarian Cancer
  • Primary Peritoneal Ca
    : 1999-11-01
    :
    • Biological: filgrastim
    • Drug: gemcitabine h

Terminated : Liposomal Doxorubicin and Etoposide in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer
:
  • Fallopian Tube Cancer
  • Ovarian Cancer
  • Primary Peritoneal Ca
    : 1999-11-01
    :
    • Drug: etoposide
    • Drug: pegylated liposomal

Completed : Cisplatin and Gemcitabine in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
:
  • Fallopian Tube Cancer
  • Ovarian Cancer
  • Primary Peritoneal Ca
    : 1999-11-01
    :
    • Drug: chemotherapy
    • Drug: cisplatin

Completed : Cisplatin Plus Irinotecan in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer
:
  • Fallopian Tube Cancer
  • Ovarian Cancer
  • Primary Peritoneal Ca
    : 1999-11-01
    :
    • Drug: cisplatin
    • Drug: irinotecan hydrochlo

Completed : Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer
:
  • Ovarian Cancer
  • Primary Peritoneal Cavity Cancer

: 1999-11-01
:
  • Drug: cisplatin
  • Drug: paclitaxel

Completed : Weekly Infusions of Paclitaxel in Treating Women With Stage III or Stage IV Ovarian Cancer Refractory to Paclitaxel and Platinum
:
  • Fallopian Tube Cancer
  • Ovarian Cancer
  • Primary Peritoneal Ca
    : 1999-11-01
    : Drug: paclitaxel
Completed : Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Epithelial Ovarian Cancer or Primary Peritoneal Cancer
:
  • Ovarian Cancer
  • Primary Peritoneal Cavity Cancer

: 1999-11-01
:
  • Biological: filgrastim
  • Drug: amifostine tr

Completed : S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission
:
  • Fallopian Tube Cancer
  • Ovarian Cancer
  • Peritoneal Cavity Can
    : 1999-11-01
    : Drug: paclitaxel 135 mg/m2 IV every 28 days Other Na
Completed : Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Persistent Epithelial Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancer
:
  • Fallopian Tube Cancer
  • Ovarian Cancer
  • Primary Peritoneal Ca
    : 1999-11-01
    :
    • Biological: filgrastim
    • Drug: carboplatin

<<< Previous | Next >>>
Orthopedics Health
Orthopedics Health WebHealth Network Media
  • WebHealthNetwork
  • DiabetesHealthMatters
  • HeartandStrokeHealth
  • WomensHealthCareCommunity
  • AsthmaHealthCenter
  • CancerHealthCenter
  • MentalHealthHelpCenter
  • Skincarehealthcenter
  • DigestiveTractHealth
  • VaccineHealthCenter
  • PainHealthCenter
  • FightingAddictionCenter
  • ObesityHealthMatters
  • SeniorHealthcareMatters
  • BrainAndNerveCenter
  • PediatricsHealthCenter
  • RareDiseasesHealthCenter
  • Wealth Mason
  • Home Owners Circle
  • EasyInsuranceFinder
  • EduJumpStart
  • SaleSpider
  • ScoopCafe
  • SaleSpiderMedia
  • Viewpoint.World
  • TravelerBooked
  • TechNewsBytes
  • Contact Us
  • Advertising Privacy Policy

This site uses cookies for analytics and advertising. No personal information is collected.

© Orthopedics Health .

We use cookies to enhance your experience, analyze anonymized traffic, and deliver personalized content and ads. No personal information is collected. By using our website, you consent to our use of cookies and agree to our data practices as described in our Privacy Policy. To Reject, please change your browser settings.